$3,000.00
PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Explore and visualize revenue dynamics in Acorda’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.
5 OVERVIEW
5 Snapshot
5 Model updates
5 Analysis structure
7 Q4 2017 REVIEW
7 Acorda’s future hinges on the commercial success of a single late-stage adjunctive treatment for Parkinson’s disease
10 Q3 2017 REVIEW
10 Under-pressure Acorda forced to focus on most de-risked pipeline asset
14 STRATEGY ANALYSIS
14 Restructuring in the face of Ampyra generic competition
14 Acorda’s future hinges on a successful launch of Inbrija
14 Semi-successful acquisitions
14 ARCUS platform technology
15 Acorda cannot afford distractions
15 Long-term outlook
15 Will Acorda be an M&A target in 2018, and for who?
15 What price for Acorda?
16 Approaching the precipice of an undefined sales cliff does not constitute ideal selling conditions
16 Acorda’s SWOT analysis
17 Acorda’s key events and catalysts
19 PORTFOLIO ANALYSIS
21 Q4 2017
22 Q3 2017
22 Q2 2017
24 FACTS AND FIGURES
24 Acorda’s prescription pharma sales outlook
24 Acorda’s regional pharma sales outlook
26 Acorda’s therapy area dynamics
30 Acorda’s growth drivers and resistors
32 Acorda’s lifecycle analysis
34 Acorda’s M&A strategy and history
37 BIBLIOGRAPHY
LIST OF FIGURES
24 Figure 1: Acorda’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
26 Figure 2: Acorda’s therapy area dynamics, 2017–27
32 Figure 3: Acorda’s launch/core/expiry portfolio configuration, 2017–27
LIST OF TABLES
20 Table 1: Acorda’s sales by therapy area ($m), 2017–27
25 Table 2: Acorda’s prescription pharmaceutical sales by region ($m), 2017–27
27 Table 3: Acorda’s sales by therapy area ($m), 2017–27
29 Table 4: Acorda’s central nervous system portfolio sales, by product ($m), 2017–27
31 Table 5: Acorda’s key products, 2017–27
33 Table 6: Acorda’s sales by launch, core, and expiry portfolio ($m), 2017–27
35 Table 7: Acorda’s key merger and acquisition deals, 2012–18
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!